Volume | 39,784 |
|
|||||
News | - | ||||||
Day High | 4.75 | Low High |
|||||
Day Low | 4.36 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Eagle Pharmaceuticals Inc | EGRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.36 | 4.36 | 4.75 | 4.39 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
757 | 39,784 | $ 4.49 | $ 178,447 | - | 4.10 - 30.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:51:37 | 1 | $ 4.6001 | USD |
Eagle Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
59.22M | 12.99M | - | 316.61M | 35.64M | 2.74 | 1.66 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Eagle Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EGRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.70 | 5.26 | 4.28 | 4.87 | 176,115 | -0.10 | -2.13% |
1 Month | 5.73 | 5.82 | 4.28 | 4.92 | 158,217 | -1.13 | -19.72% |
3 Months | 5.02 | 6.81 | 4.28 | 5.48 | 188,613 | -0.42 | -8.37% |
6 Months | 13.71 | 14.78 | 4.10 | 5.95 | 218,838 | -9.11 | -66.45% |
1 Year | 28.97 | 30.40 | 4.10 | 11.51 | 188,188 | -24.37 | -84.12% |
3 Years | 43.97 | 58.25 | 4.10 | 28.30 | 152,357 | -39.37 | -89.54% |
5 Years | 47.16 | 64.94 | 4.10 | 36.97 | 152,059 | -42.56 | -90.25% |
Eagle Pharmaceuticals Description
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration. |